IAM · ISSUER CIK 1997038
Iambic Therapeutics, Inc.
Between Jul 31, 2026 and Oct 28, 2026, 9 Iambic Therapeutics, Inc. insiders reported $11.5M of open-market purchases and $0.00 of sales on SEC Form 4. The largest buyer was Rachlin Evan Lockwood (Director), with $11.5M.
↗9 insiders filed
Original Form 4 filings from Jul 31, 2026 to Oct 28, 2026. No open-market sales in the window.
$11.5MInsider buying
$0.00Insider selling
+$11.5MNet open-market
Oct 19, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 19, 202620:20 | Oct 16, 2026 | IAM | 10% Owner · +4 joint | C · Convert | — | +4,196,585 | 742,546 | — | — | ||
| Oct 19, 202619:53 | Oct 16, 2026 | IAM | Director | C · Convert | — | +4,196,585 | 742,546 | — | — | ||
| Oct 19, 202619:51 | Oct 16, 2026 | IAM | CFO & Chief Corp Dev Ofcr | C · Convert | — | +61,342 | 279,902 | +28% | — | ||
| Oct 19, 202619:49 | Oct 16, 2026 | IAM | Director, Chairperson of the Board | C · Convert | — | +200,920 | 200,920 | New | — | ||
| Oct 19, 202619:47 | Oct 16, 2026 | IAM | Director | P · Buy | $16.00 | +718,750 | 2,588,248 | +38% | +$11.5M | -15.4% | -7.6% |
| Oct 19, 202619:47 | Oct 16, 2026 | IAM | Director | C · Convert | — | +1,927,252 | 57,754 | — | — | ||
| Oct 16, 202616:16 | Oct 14, 2026 | IAM | CFO & Chief Corp Dev Ofcr | A · Grant | — | +28,400 | 218,560 | +15% | — | ||
| Oct 16, 202616:14 | Oct 14, 2026 | IAM | Chief Scientific Officer | A · Grant | — | +19,500 | 30,909 | +171% | — | ||
| Oct 16, 202616:12 | Oct 14, 2026 | IAM | Chief Medical Officer | A · Grant | — | +31,000 | 71,459 | +77% | — | ||
| Oct 16, 202616:09 | Oct 14, 2026 | IAM | Chief Technology Officer, Director | A · Grant | — | +132,200 | 1,862,665 | +8% | — | ||
| Oct 16, 202616:07 | Oct 14, 2026 | IAM | Chief Executive Officer, Director | A · Grant | — | +132,200 | 1,410,756 | +10% | — |